{'52WeekChange': 0.22592592,
 'SandP52WeekChange': 0.0644362,
 'address1': 'One Gateway Center',
 'address2': 'Suite 351',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.31,
 'askSize': 1000,
 'averageDailyVolume10Day': 216800,
 'averageVolume': 278292,
 'averageVolume10days': 216800,
 'beta': 1.686018,
 'beta3Year': None,
 'bid': 3.21,
 'bidSize': 1000,
 'bookValue': 1.395,
 'category': None,
 'circulatingSupply': None,
 'city': 'Newton',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.35,
 'dayLow': 3.22,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.093,
 'enterpriseToRevenue': None,
 'enterpriseValue': 27452998,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.326857,
 'fiftyTwoWeekHigh': 7.25,
 'fiftyTwoWeekLow': 1.08,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 3055896,
 'forwardEps': -1.2,
 'forwardPE': -2.7583332,
 'fromCurrency': None,
 'fullTimeEmployees': 18,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.24643,
 'heldPercentInstitutions': 0.51929003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1505952000,
 'lastSplitFactor': '96:1000',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/acertx.com',
 'longBusinessSummary': 'Acer Therapeutics Inc., a pharmaceutical company, '
                        'focuses on the acquisition, development, and '
                        'commercialization of therapies for serious rare and '
                        'life-threatening diseases. Its pipeline includes '
                        'three clinical-stage candidates: EDSIVO for the '
                        'treatment of vascular Ehlers-Danlos Syndrome in '
                        'patients with a confirmed type III collagen mutation; '
                        'and ACER-001, a formulation of sodium phenylbutyrate '
                        'for the treatment of various inborn errors of '
                        'metabolism, including urea cycle disorders, maple '
                        'syrup urine disease, and osanetant for the treatment '
                        'of induced Vasomotor Symptoms. The company has a '
                        'research collaboration agreement with the National '
                        'Center for Advancing Translational Sciences (NCATS) '
                        'to develop emetine hydrochloride as a potential '
                        'treatment for patients with COVID-19; and a license '
                        'agreement with Sanofi to acquire worldwide rights to '
                        'osanetant, a clinical-stage, selective, and '
                        'non-peptide tachykinin NK3 receptor antagonist. Acer '
                        'Therapeutics Inc. was founded in 2013 and is '
                        'headquartered in Newton, Massachusetts.',
 'longName': 'Acer Therapeutics Inc.',
 'market': 'us_market',
 'marketCap': 33924852,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_254831560',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -26397972,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.28,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '844 902 6100',
 'previousClose': 3.27,
 'priceHint': 4,
 'priceToBook': 2.3727598,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.35,
 'regularMarketDayLow': 3.22,
 'regularMarketOpen': 3.28,
 'regularMarketPreviousClose': 3.27,
 'regularMarketPrice': 3.28,
 'regularMarketVolume': 51669,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 10249200,
 'sharesPercentSharesOut': 0.037,
 'sharesShort': 378795,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 532702,
 'shortName': 'Acer Therapeutics Inc.',
 'shortPercentOfFloat': 0.066700004,
 'shortRatio': 1.5,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ACER',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.615,
 'twoHundredDayAverage': 3.2423022,
 'volume': 51669,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.acertx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02458'}